ALFA Filings
Every announcement, straight from the exchange
Every regulatory approval announcement on NSE and BSE that our alert engine sent, newest first.
Time
346 announcements with these filters
Torrent Pharmaceuticals Limited received a clean report from the USFDA for its Bileshwarpura (Oncology) facility. The inspection, conducted from April 6 to April 10, 2026, concluded with zero observations. This successful regulatory outcome confirms compliance with international manufacturing standards for the oncology site.
Pratiksha Chemicals Limited has received ROC approval to change its name to Vellora Impact Limited, effective April 10, 2026. The Registrar of Companies issued a fresh Certificate of Incorporation following shareholder approval via postal ballot. The company is now updating its records with the Stock Exchange.
AstraZeneca Pharma India Ltd received CDSCO approval to import and market Calquence (Acalabrutinib 100mg) for treating previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma. This additional indication expands the drug's therapeutic reach in the Indian market, subject to final statutory approvals.
Niva Bupa Health Insurance Company Ltd received IRDAI approval for the transfer of up to 14,62,02,091 equity shares by its existing investor, Fettle Tone LLP. The approval was granted under Section 6A of the Insurance Act, 1938. This regulatory clearance facilitates a significant shareholding transfer within the company's investor base.
BSE has received SEBI approval to launch derivative contracts on the 'BSE Focused IT Index'. This sector index tracks the performance of 14 IT companies. The approval enables BSE to expand its derivatives product suite, with contract specifications to be announced via separate circulars.
Srinibas Pradhan Constructions Ltd. has received 'A Class' P.W.D. Contractors Registration from the Works Department, Odisha. This license, valid until March 31, 2028, enables the company to participate in government infrastructure tenders, enhancing its eligibility for future business growth.
Glenmark Pharmaceuticals received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg. The product targets a market with annual sales of approximately ₹544.64 Crore ($59.2 million). This approval strengthens Glenmark's women's healthcare portfolio in the U.S. market.
Lupin Limited received U.S. FDA approval for its generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, bioequivalent to Xigduo® XR. The company also secured tentative approval for a 2.5 mg/1,000 mg variant. This regulatory milestone enables Lupin to market the anti-diabetic medication in the United States, expanding its metabolic therapy portfolio.
Torrent Power Limited has received approval from the Competition Commission of India to acquire a 100% stake in Nabha Power Limited from L&T Power Development Limited. This regulatory clearance is a key milestone for completing the previously announced strategic acquisition.
Zydus Lifesciences received final USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), used for type 2 diabetes. The drug had annual US sales of approximately ₹94,860 Crore. Zydus is eligible for 180 days of shared generic exclusivity, with manufacturing based in Ahmedabad SEZ.
Biocon Pharma, a subsidiary of Biocon Limited, received U.S. FDA approval for Dapagliflozin Tablets (5 mg and 10 mg) for treating type 2 diabetes. The product will be manufactured at Biocon's FDA-approved facilities. This approval strengthens Biocon's global diabetes portfolio, covering oral solids, biosimilar insulins, and GLP-1 peptides.
Lemon Tree Hotels received CCI approval for Coastal Cedar Investments BV to acquire equity shares in Fleur Hotels Limited. The approval also covers an internal group restructuring involving amalgamation and demerger. This regulatory milestone is a key step toward completing the proposed transactions.
Aditya Birla Capital received CCI approval for a Rs. 2,750 Crore primary capital investment into its subsidiary, Aditya Birla Housing Finance, by Advent International. This regulatory clearance allows the transaction to proceed, strengthening the subsidiary's growth capital following the Board's February 2026 approval.
Prime Cable Industries Limited has obtained a BIS license for manufacturing solar cables up to 1500 V d.c. at its Rajasthan plant. Valid until 2031, this approval enables entry into high-value government and renewable energy markets. The certification enhances product reliability and aligns with mandatory standards for utility-scale photovoltaic systems.
Aurobindo Pharma received USFDA approval for Dapagliflozin and Metformin Hydrochloride ER Tablets, targeting a US$ 514 Million (₹4,780.2 Crore) market. The product, bioequivalent to AstraZeneca's Xigduo XR, will be manufactured at APL Healthcare's Unit-IV and launched immediately with 180 days of shared exclusivity.
Aurobindo Pharma received USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), addressing a US$ 10.2 billion market. The product, bioequivalent to Farxiga, will be manufactured at APL Healthcare's Unit-IV and launched immediately with 180 days of shared generic exclusivity.